兰州大学学报（医学版）2024，Vol.50Issue(11)：87-94,8.DOI:10.13885/j.issn.1000-2812.2024.11.012
耐多药结核病化学治疗进展
Progress in chemotherapy of multidrug-resistant tuberculosis
摘要
Abstract
Multidrug-resistant tuberculosis(MDR-TB)means that Mycobacterium tuberculosis is resistant to at least two first-line anti-tuberculosis drugs,including isoniazid and rifampicin.Because of its long course of tuberculosis,high economic burden,low cure rate and great differences in drug resistance in different coun-tries and regions,this disease has posed great challenges to the global tuberculosis prevention and control.Therefore,it is an urgent task to actively explore the effective treatment of multidrug-resistant tuberculosis.At present,chemotherapy is yet the main treatment for MDR-TB.This paper expounds on chemotherapy for MDR-TB,and discusses the existing limitations and shortcomings in order to provide some reference for clini-cal treatment and multidisciplinary cooperation of MDR-TB.关键词
耐多药/结核病/化学治疗/结核分枝杆菌/进展Key words
multidrug-resistant/tuberculosis/chemotherapy/mycobacterium tuberculosis/progress分类
医药卫生引用本文复制引用
刁婷婷,刘超,张红吉,欧阳兵,李晓非..耐多药结核病化学治疗进展[J].兰州大学学报（医学版）,2024,50(11):87-94,8.基金项目
云南省科技厅高校联合重点项目(2020001BA070001-136) （2020001BA070001-136）
昆明市科技计划项目(2023-1-NS-008) （2023-1-NS-008）
